1. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31:858-873. 2. Seeman MV. Gender differences in schizophrenia. Can J Psychiatry. 1982;27:107-112. 3. Seeman MV. Interaction of sex, age, and neuroleptic dose. Comp Psychiatry. 1983;24:125-128. 4. Usall J, Suarez D, Haro JM, and the SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153: 225-231. 5. Hare E, Glahn DC, Dassori A, et al. Heritability of age of onset of psychosis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 6 [Epub ahead of print]. 6. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. 2004;161:1324-1333. 7. Marin R, Guerra B, Alonso R, et al. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr Neurovasc Res. 2005;2:287-301. 8. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16:185-194. 9. Castle DJ, Abel K, Takei N, et al. Gender differences in schizophrenia: hormonal effect or subtypes? Schizophr Bull. 1995;21:1-12. 10. Häfner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry. 1997;42:139-151. 11. Grossman LS, Harrow M, Rosen C, et al. Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery. Compr Psychiatry. 2008;49:523-529. 12. Kajantie E, Phillips DI. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology. 2006;31:151-178. 13. Riecher-Rössler A, Löffler W, Munk-Jörgensen P. What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci. 1997;247:195-208. 14. Lindamer LA, Lohr JB, Harris MJ, et al. Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry. 1999;60:61-67. 15. Seeman MV. Does menopause intensify symptoms in schizophrenia? In: Lewis-Hall F, Williams TS, Panetta JA, et al, eds. Psychiatric illness in women: emerging treatments and research. Arlington, VA: American Psychiatric Publishing, Inc.; 2002:239-248. 16. Convert H, Védie C, Paulin P. [Late-onset schizophrenia or chronic delusion]. Encephale. 2006;32:957-961. 17. Sato T, Bottlender R, Schröter A, et al. Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. Schizophr Res. 2004;67:175-183. 18. Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry. 2001;9:51-58. 19. Weiss DB, Dyrud J, House RM, et al. Psychiatric manifestations of autoimmune disorders. Curr Treat Options Neurol. 2005;7:413-417. 20. Castagnini A, Bertelsen A, Munk-Jorgensen P, et al. The relationship of reactive psychosis and ICD-10 acute and transient psychotic disorders: evidence from a case register-based comparison. Psychopathology. 2007;40:47-53. 21. Huber TJ, Rollnik J, Wilhelms J, et al. Estradiol levels in psychotic disorders. Psychoneuroendocrinology. 2001;26: 27-35. 22. Heiss G, Wallace R, Anderson G, et al, for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9):1036-1045. 23. Doncarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology. 2009 May 15 [Epub ahead of print]. 24. Wong J, Seeman MV, Shapiro H. Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatr Psychiatry. 2003;11(6):697-698. 25. Ye L, Chan MY, Leung LK. The soy isoflavone genistein induces estrogen synthesis in an extragonadal pathway. Mol Cell Endocrinol. 2009;302:73-80. 26. Kulkarni J, Gurvich C, Gilbert H, et al. Hormone modulation: a novel therapeutic approach for women with severe mental illness. Aust N Z J Psychiatry. 2008;42:83-88.